Fosun pharma (02196.HK) spent 1.8 million HKD to repurchase 128,000 shares on November 25.

On November 25th, Gelonhui announced that fosun pharma (02196.HK) issued a notice to repurchase 0.128 million shares for 1.8 million Hong Kong dollars on November 25, 2024, at a repurchase price of 14-14.1 Hong Kong dollars per share.

Gelonghui FinanceNov 25 04:50 ET

Shanghai Fosun Pharma Moves Forward With Henlius Merger

TipRanksNov 22 05:40 ET

Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.

①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?

cls.cnNov 19 22:50 ET

Jiuyuan Genomics (02566.HK) is expected to be listed on November 28, with multiple cornerstone investors including fosun pharma.

Genomics Nine Limited (02566.HK) has announced that the company plans to globally offer 45.3988 million H shares, with 4.54 million shares to be offered in Hong Kong, and 40.8588 million shares to be offered internationally; the IPO will take place from November 20 to November 25, 2024, with the expected pricing date being November 26; the offer price will be between HK$11.48 and HK$12.56 per share, with a trading unit of 200 shares per board lot; Huatai International is the sole sponsor; the anticipated shares will commence trading on the Stock Exchange of Hong Kong on November 28, 2024.

Gelonghui FinanceNov 19 18:03 ET

Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation

①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.

cls.cnNov 19 08:17 ET

Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.

cls.cnNov 13 08:52 ET